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Psychiatric symptoms (PS) can be non-motor features in Parkinson’s disease (PD) which
are common even in the prodromal, untreated phase of the disease. Some PS, especially
depression and anxiety recently became known predictive markers for PD. Our objective
was to explore retrospectively the prevalence of PS before the diagnosis of PD.
Methods
In the framework of the Hungarian Brain Research Program we created a database from
medical and medication reports submitted for reimbursement purposes to the National
Health Insurance Fund in Hungary, a country with 10 million inhabitants and a single payer
health insurance system. We used record linkage to evaluate the prevalence of PS before
the diagnosis of PD and compared that with patients with ischemic cerebrovascular lesion
(ICL) in the period between 2004–2016 using ICD-10 codes of G20 for PD, I63-64 for ICL
and F00-F99 for PS. We included only those patients who got their PD, ICL and psychiatric
diagnosis at least twice.
Results
There were 79 795 patients with PD and 676 874 patients with ICL. Of the PD patients 16%
whereas of those with ischemic cerebrovascular lesion 9.7% had a psychiatric diagnosis
before the first appearance of PD or ICL (p<0.001) established in psychiatric care at least
twice. The higher rate of PS in PD compared to ICL remained significant after controlling for
age and gender in logistic regression analysis. The difference between PD and ICL was sig-
nificant for Mood disorders (F30-F39), Organic, including symptomatic, mental disorders
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(F00-F09), Neurotic, stress-related and somatoform disorders (F40-F48) and Schizophre-
nia, schizotypal and delusional disorders (F20-F29) diagnosis categories (p<0.001, for all).
Discussion
The higher rate of psychiatric morbidity in the premotor phase of PD may reflect neurotrans-
mitter changes in the early phase of PD.
Introduction
Parkinson’s disease (PD) is a gradual-onset multisystem neurodegenerative disorder, currently
clinically defined by a set of classical motor signs. However, converging evidence from neuro-
pathological, clinical, and imaging research suggests a definable prodromal phase where
detectable non-motor features are major components [1–3]. Psychiatric symptoms (PS) are
some of the non-motor features which are common even in the prodromal, untreated phase of
PD, may precede motor symptoms and have a major impact on the course of the disease, qual-
ity of life and caregivers [4, 5]. Some PS, especially depression and anxiety recently became
known predictive markers for PD with several prospective studies reporting diagnostic value
[3]. To explore PS that are related to PD itself it is necessary to study the prodromal phase and
untreated patients as antiparkinsonian drugs have the potential to influence cognition, affec-
tive, psychotic and impulsivity symptoms. We recently reviewed the literature on PS address-
ing the early, untreated stages of PD, with a focus on the premotor and early motor phases
separately and found that the prevalence of PS is high even in the premotor/prodromal phase
[6]. The onset and characteristics of PS in drug naïve patients before the diagnosis of PD are
still not well studied, further examination of patients in the premotor, untreated phase is
needed to better understand PS which are linked to the disease pathology itself. Recently, we
demonstrated that incidence and prevalence rates of PD are considerably higher than previous
reports in Hungary and the healthcare administrative database of the National Health Insur-
ance Fund (NHIF), using the International Classification of Diseases 10th revision (ICD-10),
with proper case identification and certification methodology is appropriate to evaluate epide-
miological features of PD in Hungary [7]. Therefore, using this database with a massive sample
size our objective was to explore retrospectively the prevalence of PS before the diagnosis of
PD in the Hungarian population.
Materials and methods
We identified PD patients with PS using the database of the NHIF which includes data from
specialist outpatient and specialist inpatient services of all hospitals covering the whole popula-
tion of Hungary. The NHIF does not include data from general practitioners. Encrypted iden-
tifiers were used as the original patient identifier codes were anonymized. The database
contains information of PD patients covering a 13-year period between 2004 and 2016. Case
ascertainment and patient selection are described in detail in a previous paper [7]. First,
patients who used either the inpatient or the outpatient specialist health care service at least
once during this period and had a primary or secondary diagnosis of PD (ICD-10, G20) were
identified. We considered those patients to have PD who appeared at least in two calendar
years with G20 code in the database during the 13-year period regardless of the diagnosis type
(i.e., primary/admitting diagnosis or secondary diagnosis). This is the PD patient group that
was further analyzed. Third, the range and prevalence of all mental and behavioral disorders
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(ICD-10, codes F00-F99) were analyzed in the period before the first appearance of PD in the
database. For more conservative case ascertainment the F00-F99 diagnoses had to be estab-
lished at least twice in an outpatient or inpatient psychiatric care service. For the control group
we chose all patients with ischemic cerebrovascular lesion (ICL) diagnoses (ICD-10, codes I63
or I64) assigned at least twice between 2004 and 2016. In this group, patients with PD or par-
kinsonism (ICD-10, codes G20-26) with any diagnosis type (primary/secondary) were not
included. In both groups (PD and ICL) patients below 40 and above 100 years of age (age in
the year of the first PD or ICL diagnosis) were excluded as well as patients who refilled any
antiparkinsonian drug (APD) before their first PD or ICL diagnosis. Pharmacological data is
available only from 2010, therefore our analysis could evaluate prescriptions of APDs refilled
at pharmacies only from 2010 onwards and had no access to data on inpatient medication use
in hospitals.
Personal data protection regulations were followed, the Ethics Committee of Semmelweis
University, Budapest, Hungary approved the study (Approval No: SE TUKEB 88/2015).
Data extraction and results of individual searches in the database were exported to excel
files. This was performed by a research assistant IT specialist, with several years of experience
in reviewing medical records of patients with neurological conditions. The data from excel
files were first analyzed by basic descriptive statistical methods. For associations between the
PD and ICL group we used chi-squared test, logistic regression and mixed effects logistic
regression analysis. The goodness of fit testing of the traditional logistic regression models was
considered using the Hosmer-Lemeshow test but was eventually not used due to the large sam-
ple size, which resulted in significant test outcomes even when there was only a minor devia-
tion. R version 3.6.2 was used for data analysis with packages lme4 and Resource selection.
Results
The number of patients between 2004–2016 with at least one PD diagnosis (G20) in the spe-
cialist healthcare service (outpatient and inpatient) was 130 773. Fulfillment of the minimum
2-year PD diagnosis criteria was present in 79 795 patients, this was the cohort for further anal-
ysis. The mean ± SD age of this group was 73 ± 9 years, 48% were male. Of the 79 795, 59 403
patients had at least one mental and behavioral disorder (F00-F99) anytime during the exam-
ined 13 year period. The number of patients who had their F00-F99 diagnosis before the first
PD diagnosis was 26 645. Out of the 26 645 patients 13 092 had their F00-F99 diagnosis in spe-
cialized psychiatric care (outpatient/inpatient) established at least twice.
The control group between 2004 and 2016 with at least one ICL diagnosis (I63 or I64) and
without PD diagnosis consisted of 783 843 patients. Of those 676 874 got their ICL diagnosis at
least twice. The mean ± SD age of this group was 69 ± 12 years, 46% were male. 330 170
patients with ICL had at least one F00-F99 diagnosis during the studied 13 years. Of those, 160
501 had their psychiatric diagnosis before the diagnosis of ICL, and out of the 160 501 patients
66 164 had their F00-F99 diagnosis established in psychiatric care at least twice. Fig 1 shows
the algorithm used for cohort definition.
To evaluate the overall presence of psychiatric morbidity, in addition to the number of
patients we also analyzed the total number of reported F00-F99 diagnoses, noting, that an indi-
vidual patient may have several diagnoses in the F00-F99 categories. The numbers of all F00-
99 diagnoses before the initial PD and ICL diagnosis were 63 360 vs. 340 280, and of those
established in psychiatric care were 25 674 vs. 123 746 for PD and ICL, respectively. Table 1
shows the number of patients and their mean age at the first diagnosis. Table 2 presents the
number of diagnoses that were established in psychiatric care at least twice, their proportion in
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all 79 795 PD and all 676 874 ICL patients and the effect of age and gender. Table 3 presents
the age of patient subgroups by F-categories.
Of the PD patients 16% whereas of those with ICL 9.7% had a psychiatric diagnosis before
the first appearance of PD or ICL (p<0.001). The higher rate of PS in PD compared to ICL
Fig 1. Flow chart of patients’ selection. �APD-antiparkinsonian drug.
https://doi.org/10.1371/journal.pone.0236728.g001
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remained significant after controlling for age and gender in logistic regression analysis
(p<0.01 for age, gender and diagnosis type). We found that females had greater odds com-
pared to males, and older patients had lowers odds of preceding psychiatric diagnoses. In the
PD group where psychiatric diagnosis appeared before PD diagnosis, in descending order
Mood disorders (F30-F39: 9%), Organic, including symptomatic, mental disorders (F00-F09:
9%), Neurotic, stress-related and somatoform disorders (F40-F48: 7%) and Schizophrenia,
schizotypal and delusional disorders (F20-F29: 4%) were the most common diagnosis catego-
ries, compared with only 6% (p<0.001), 4% (p<0.001), 5% (p<0.001) and 1% (p<0.001) in
the ICL group in the same categories.
The number of psychiatric diagnoses in total and for the sub-diagnoses were also analyzed
using traditional logistic and mixed effects logistic regression analysis. The traditional models
were used simply on the psychiatric diagnoses as an outcome variable while the mixed effects
model also took into account that several diagnoses may belong to the same patient. Analyses
were conducted with and without controlling for the effect of age and gender.
Without controlling and with considering all types of psychiatric diagnoses together we
found that the odds of receiving a psychiatric diagnosis before a PD/ICL diagnosis is signifi-
cantly greater for the PD group (p<0.001). This was true in both types of logistic regression
models. The effect of PD diagnosis in the different psychiatric diagnosis subgroups was
varying.
When we adjusted for age and gender the results were much more consistent: the odds of
preceding any (OR: 1.429 [95% C.I: 1.395–1.464]), or F00-F09, F20-F29, F30-F39, F40-F48,
F50-F59, F60-F69 or F70-F79 diagnoses were significantly greater for the PD group of patients
in both types of logistic regression models (p<0.001 for all comparisons). The only exception
was F10-F19 (mental and behavioral disorders due to psychoactive substance use), where the
ICL group had greater odds of preceding psychiatric diagnosis. Logistic regression could not
be conducted for the sub-diagnoses of F80-89 and F99 due to lack of relevant diagnoses. The
adjusted model for the diagnoses F90-98 also had a relatively low amount of diagnoses to work
with, and while the regressions could be conducted, they did not produce any significant effect
for the PD/ICL groups. The multiple testing might warrant for correction, however the tests
were not directly comparable (as they used different sub-diagnoses i.e. different outcome vari-
ables) and the p-values were so low that the effects would remain significant even after correc-
tion, thus our overall conclusions would not change. Summing up the effect of gender and age,
generally we found that females had greater odds compared to males, and older patients had
lowers odds of preceding psychiatric diagnoses. The results of the mixed effects multiple logis-
tic regression models are shown in Table 2. We also conducted a sensitivity analysis where we
only kept the data of such psychiatric diagnoses where medication information was also avail-
able. The results of the controlled mixed effects logistic regression models were very close to
Table 1. Age of the patient subgroups.
Patient subgroup PD (n) Mean age (±SD) at initial appearance
of G20
ICL (n) Mean age (±SD) at initial appearance of
I63-I64
All patients 79 795 73.2 ± 9.0 676
874
69 ± 12
Patients with F00-99 dg. 59 403 72.9 ± 9.2 330
170
67.7 ± 12.1
Patients with F00-99 dg. before PD/ICL dg. 26 645 72.1 ± 9.5 160
501
66.4 ± 12.2
Patients with F00-99 dg. established in psychiatric care before
PD/ICL dg.
13 092 71.3 ± 10 66 164 65.1 ± 12.3
https://doi.org/10.1371/journal.pone.0236728.t001
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the original ones. However, due to the severely decreased number of patients in the sensitivity
analysis the effect of PD/ICL diagnosis lost its significance on the preceding F10-19, F50-59,
F60-69, F70-79 sub-diagnoses.
Fig 2A presents the distribution of F00-F99 diagnoses in proportion of all PD (79 795) and
ICL (676 874) patients, and Fig 2B shows the distribution of diagnoses which were established
in specialized psychiatric care. In both figures an individual patient may have appeared repeat-
edly in an F subgroup and also in several F subgroups if that patient had been assigned multi-
ple F codes. The average time when psychiatric diagnoses appeared before PD diagnosis was
3.1 years in the PD group and 4 years in ICL.
Table 2. Number of F00-F99 diagnoses which were established in psychiatric care before PD and ICL diagnoses between 2004–2016 in the ICD-10 subgroups and
the effect of the presence of PD vs. ICL, age and gender on F00-99 diagnoses.
ICD
code
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�: An individual patient may appear repeatedly in an F subgroup and also in several F subgroups if that patient had been assigned multiple F codes.
https://doi.org/10.1371/journal.pone.0236728.t002
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Discussion
By analyzing the large healthcare administrative database of the NHIF our aim was to estimate
the prevalence of mental and behavioral disorders before the diagnosis of PD. Our primary
findings were that several psychiatric diseases (especially mood disorders, cognitive
impairment, anxiety disorders, schizophrenia) were more common in PD patients before PD
diagnosis compared to our control group, patients with ICL. If we consider only those diagno-
ses that were established by psychiatric care, the numbers are still significantly higher in PD
than in the control group. Our results are in line with previous findings and support the notion
that a range of PS are already present at the diagnosis of PD, and these symptoms are more
common in PD patients than in people without PD [4, 8]. Henceforth, we will discuss below
only the most common PS that we have found.
Our data indicate that from the Organic, including symptomatic, mental disorders group
(F00-09) category the diagnosis rate in PD patients was 9%, most of which were different types
of dementias, showing evidence of cognitive dysfunction. In comparison, only 4% of those
with ICL had diagnoses from the F00-09 group. It was previously demonstrated that the preva-
lence of cognitive impairment is high even in newly diagnosed PD patients, it is associated
with extensive atrophy and greater percentage of cortical thinning, older age at disease onset is
an important determinant of cognitive dysfunction [9–11] and up to 80% of all PD patients
will eventually develop dementia [12]. Our results support these findings because in our
PD sample the average age in the year of the appearance of the first PD diagnosis in our data-
base was relatively high, 73 years. Although we do not have information on detailed
Table 3. Age of patients for F00-99 diagnosis categories between 2004–2016 for those where F diagnoses were assigned at least twice by psychiatric care facilities.
ICD
code
Title Mean age at F00-99
dg. in PD (±SD)
N� Mean age (±SD) at
initial appearance of
G20
Mean age at F00-99
dg. in ICL (±SD)




Organic, including symptomatic, mental
disorders





Mental and behavioral disorders due to
psychoactive substance use
62 ± 9.7 584 65.6 ± 9.2 55.1 ± 9.7 6768 59.5 ± 9.3
F20-
29
Schizophrenia, schizotypal and delusional
disorders
65.4 ± 11.3 2914 68.2 ± 10.8 62.1 ± 13.2 6981 66 ± 12.5
F30-
39





Neurotic, stress-related and somatoform
disorders





Behavioral syndromes associated with
physiological disturbances and physical
factors
66.4 ± 10.3 461 69.1 ± 10 59.6 ± 11.4 2227 63 ± 11.3
F60-
69
Disorders of adult personality and behavior 60.6 ± 10.2 557 64.5 ± 9.9 52.4 ± 9.1 4262 56.7 ± 9.2
F70-
79
Mental retardation 54.1 ± 10.4 268 58 ± 10.2 52 ± 9.8 1379 56 ± 9.4
F80-
89
Disorders of psychological development no data 0 no data 49 ± 4.9 6 51.8 ± 4.3
F90-
98
Behavioral and emotional disorders with
onset usually occurring in childhood and
adolescence
70.8 ± 11 58 73.3 ± 10.4 64.7 ± 14.1 269 68 ± 13.2
F99 Unspecified mental disorder no data 0 no data 49.6 ± 5.5 3 56 ± 2
�: An individual patient may appear repeatedly in an F subgroup and also in several F subgroups if that patient had been assigned multiple F codes.
https://doi.org/10.1371/journal.pone.0236728.t003
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neuropsychological results, we assume that the presence of the large number of dementia diag-
noses may be due to the relatively older age of the patients. PD typically occurs in people over
the age of 60 [13]. It has to be acknowledged that the mean age at the first appearance of G20
diagnosis in our dataset was at the higher end of those in the literature. However, in a French
study which assessed PD with a similar methodology, using the national healthcare insurance
database, incidence rates were the highest starting from the 74 age group [14]. Additionally, a
study conducted in Germany, which examined prevalence and incidence based also on health
claims data, the mean age of PD onset was 77 years [15]. A systematic review of incidence
Fig 2. (A) Distribution of F00-F99 diagnoses in proportion of all patients with PD and ICL. (B) Distribution of F00-F99 diagnoses established in
psychiatric care at least twice, in proportion of all patients with PD and ICL. �: an individual patient may appear repeatedly in an F subgroup and
also in several F subgroups if that patient had been assigned multiple F codes.
https://doi.org/10.1371/journal.pone.0236728.g002
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studies of PD found that PD incidence rises steadily with age to a peak occurring between the
ages of 70 to 79 [16]. The differences in large health claim data analyzes can be explained by
different validation strategies and in our case by the fact that we only considered those with
first appearance of G20 from a defined time point, i.e. starting from 2004. Therefore it is obvi-
ous that there are many cases that had been diagnosed with PD earlier than the database was
initiated, and the first appearance of these patients in the database appears long after their first
clinical diagnosis of PD.
We found significant difference also in the Schizophrenia, schizotypal and delusional disor-
ders (F20–F29) category, where schizophrenia diagnosis (F20) was the most common. In the
PD group there was a more than twofold higher prevalence (4%) compared to the control
group (1%). A study based on similar methods as ours, analyzing ICD codes retrospectively in
a large health insurance database investigated the effects of psychiatric diseases on subsequent
PD diagnosis in an Asian population and found that having a specific psychiatric disease was
independently associated with a nearly 2.3-fold increased risk of receiving a PD diagnosis
within the 6-year follow-up period, patients with schizophrenia exhibiting the highest risk of a
later PD diagnosis [17]. Our results support this result, however the exact association between
schizophrenia and PD remains to be elucidated, because there are still just a few studies with
inconclusive data which examined the connection between the two diseases. The role of dopa-
mine and dopaminergic pathways that play crucial role in both PD and schizophrenia is well-
known [18]. Current data assume that negative and cognitive symptoms in schizophrenia
anticipate the onset of positive symptoms, decreased dopamine may be responsible for these,
suggesting that schizophrenia may essentially represent a hypodopaminergic disorder after all
[19, 20]. On the other hand a few studies have proposed the idea that parkinsonism in schizo-
phrenia may not be just the consequence of neuroleptic exposure but it could be also related to
the clinical spectrum and might represent the motor side of schizophrenia manifesting in the
late phase of disease course [21–23].
In the Mood (affective) disorders (F30–F39) category the diagnosis rate was higher in the
PD sample (9%) and it was significantly larger than in the ICL group (6%). One of the most
frequent disorder before PD diagnosis was, not surprisingly the depressive episode in both PD
and ICL groups. Depressive symptoms predating PD can have diverse etiologies, although the
exact pathomechanism is still unknown. Neurobiological factors, changes in brain structure
and neuronal systems (dopaminergic, noradrenergic, and serotonergic) that are associated
with the underlying neurodegenerative processes in PD play an important role in the early
stages, later on mood reaction to the progressive disability and PD itself, psychosocial factors
or pain could also have roles in the appearance of depressive symptoms [24, 25]. Several other
studies came to the conclusion that depression may also be an independent risk factor for PD
[26, 27]. Our prevalence values correlate favorably with previous findings [6] and further sup-
port the idea of depression being a non-motor symptom already present before the diagnosis
of PD.
Another group which showed significant difference was the Neurotic, stress-related and
somatoform disorders (F40–F48) category, before PD diagnosis being present in 7%, while
before ICL only in 5%, anxiety disorders being the most common in this category. The etiology
of anxiety in PD is also multifactorial, a dysfunction in the dopaminergic system might be
implicated from the earliest stages of disease [28] likewise decreased metabolism and tissue
reduction in different brain areas may also contribute to the development of anxiety [29, 30].
Moreover, the risk of developing PD was found to be higher in a population with anxiety, also
the psychological reaction to the development of motor disability and other common anxiety
disorders described in PD like panic attacks and social phobias have an important role [31,
PLOS ONE The prevalence of psychiatric symptoms before the diagnosis of Parkinson’s disease
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32]. Our study provides further evidence on anxiety disorders having a high prevalence before
PD diagnosis.
The average number of years when psychiatric diagnoses appeared before PD diagnosis,
which was 3.1 years in our case, slightly differ from other study findings about prodromal
symptoms such as depression and anxiety that emerged 4–6 years before PD motor symptoms
appeared [33]. This lag time may correspond to the proposed beginning of the disease process
that anticipates the onset of motor symptoms by several years or even decades [34] and the dif-
ference can be explained by the relatively shorter examination period in our study.
The strength of our study lies in the large-scale epidemiologic examination and sufficient
number of cases for valid statistical comparison. The database analysis of a several years’ time
period with full coverage of a country makes this study large about PD and psychiatric comor-
bidity. The use of all categories of discharge diagnoses types (admitting diagnosis, principal
and secondary diagnoses) according to the ICD-10-CM Official Guidelines for Coding and
Reporting increases the efficacy of case identification both in PD and psychiatric illnesses.
We are aware that our research may have several limitations, therefore our results should
be interpreted within the context of these. First, diagnostic accuracy may be limited in each
patient group (PD, psychiatry, ICL) due to the lack of a direct individual clinical case certifica-
tion by a specialist in the field. Second, using health administrative databases, the possibility of
misclassification error should be considered as an important source of research bias which
threatens the validity of study results. However it was demonstrated that databases created
from hospital reports submitted for reimbursement purposes can be used reliably in Hungary
for ICL (I63-I64) epidemiological studies [35] and as previously mentioned, with appropriate
case identification methodology this is true for PD as well [7]. Additionally, patients not pre-
senting in specialized outpatient or inpatient care but only at general practitioners, patients
who have not yet been commenced on APD, undiagnosed patients, result in underestimation
of the number of patients with PD. At the same time, all this highlights the importance of treat-
ing PS from the onset of PD, taking advantage of the benefits of certain APDs, but also being
cautious of potential side effects (e.g. psychosis). That is why it is important that the diagnosis
and treatment of PD to be managed from the beginning by a neurologist specialist, as it is the
case in Central and Eastern Europe [36, 37]. Third, information on APD use is incomplete.
This could have also influenced the results nonetheless a paper reports that the majority of PS
do not worsen substantially in the first years of PD regardless of treatment, and the initiation
of antiparkinsonian therapy does not significantly improve most of these symptoms on aver-
age [8]. Despite these drawbacks, our study provides up till now not available data regarding
the current epidemiology of the psychiatric burden experienced in this large group of PD
patients.
In conclusion, we determined that a range of psychiatric illnesses have elevated prevalence
before the first diagnosis of PD compared to ICL. This study may reflect neurotransmitter
changes in the early phase of PD and highlights the importance of early, routine screening for
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